[{"id":"c0529000-1eea-42c3-9cae-d983a7189b6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05943795","created_at":"2023-07-13T18:10:45.267Z","updated_at":"2025-02-25T15:36:23.229Z","phase":"Phase 3","brief_title":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","source_id_and_acronym":"NCT05943795","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • izalontamab (SI-B001)"],"overall_status":"Recruiting","enrollment":" Enrollment 584","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-11"},{"id":"e5534d1f-e396-45b7-a321-925588805b53","acronym":"","url":"https://clinicaltrials.gov/study/NCT05668858","created_at":"2022-12-30T14:58:33.263Z","updated_at":"2024-07-02T16:35:11.326Z","phase":"Phase 1/2","brief_title":"Clinical Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT05668858","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • izalontamab (SI-B001) • danvilostomig (SI-B003)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/10/2023","start_date":" 02/10/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-04"},{"id":"258dd981-3155-4a65-b439-66d48123d14a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05020457","created_at":"2021-08-25T14:53:14.347Z","updated_at":"2024-07-02T16:35:21.410Z","phase":"Phase 2","brief_title":"SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.","source_id_and_acronym":"NCT05020457","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • paclitaxel • docetaxel • pemetrexed • izalontamab (SI-B001)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-01-31"},{"id":"11e80090-69af-4a10-8567-99e826b98c88","acronym":"","url":"https://clinicaltrials.gov/study/NCT05949606","created_at":"2023-07-20T15:09:17.002Z","updated_at":"2024-07-02T16:35:27.645Z","phase":"Phase 1/2","brief_title":"A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05949606","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • KRAS • BRAF • ALK • MET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • EGFR wild-type • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion","tags":["HER-2 • KRAS • BRAF • ALK • MET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • EGFR wild-type • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab (SI-B001) • danvilostomig (SI-B003)"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-11-29"}]